STOCK TITAN

Glaukos Corporation (GKOS) 10-Q Filings

GKOS NYSE

Here are the 10-Q quarterly reports from Glaukos Corporation (GKOS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow GKOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GKOS filings page.

Rhea-AI Summary

Glaukos Corporation (GKOS) reported third-quarter 2026 net sales of $211.0 million, versus $133.5 million a year earlier, and net income of $2.0 million versus a $16.2 million loss. Nine-month sales were $547.2 million versus $364.3 million; net loss was $36.1 million versus $54.0 million, while operating cash flow was $40.9 million versus $21.6 million used.

Glaukos completed the transition of commercial efforts and manufacturing from Photrexa to Epioxa in the third quarter; Epioxa’s permanent J-code became effective July 1, 2026. Under a September 29, 2026 agreement with the Regents of the University of California, Glaukos agreed to pay $14.1 million in exchange for release of claims relating to specified patents and a December 2014 agreement; payment occurred in October 2026.

After quarter-end, Glaukos paid $10.0 million upfront for an exclusive RevOpsis license covering one multi-specific biologic and rights to license up to four additional retinal products. Potential milestone payments total up to $875.0 million if all five products are licensed, developed and commercialized; tiered royalties range from 3% to 8% of annual net sales. It also entered a development and lease agreement for a Huntsville facility, with approximately $42.0 million in expected multi-year project costs, and agreed to acquire an Aliso Viejo building for $15.2 million. The building agreement remains subject to closing conditions and is not expected to close until mid- to late-2027.

Rhea-AI Summary

Glaukos Corporation reported 50% year‑over‑year net sales growth for the quarter ended June 30, 2026, with net sales of $185.6 million versus $124.1 million, and six‑month net sales of $336.2 million versus $230.8 million. Gross margin improved to 82% in Q2 from 78%, helped by higher‑priced iDose TR glaucoma implants and growing Epioxa corneal therapy sales.

Operating expenses rose 41% to $168.9 million, reflecting expanded commercial infrastructure, R&D spending and higher stock‑based compensation, resulting in a Q2 net loss of $18.4 million and a six‑month net loss of $38.2 million. The company held $289.3 million in cash, cash equivalents, short‑term investments and restricted cash, alongside an accumulated deficit of $971.3 million.

Growth was led by U.S. glaucoma revenue (up 64%) and corneal health revenue (up 48%), plus double‑digit international glaucoma growth aided by foreign‑exchange tailwinds. Important updates included a permanent HCPCS J‑code (J2789) for Epioxa effective July 1, 2026, proposed Medicare coverage determinations for iDose TR, and an ongoing commercial transition from Photrexa to Epioxa.

Rhea-AI Summary

Glaukos Corporation reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $150.6 million from $106.7 million a year earlier, driven mainly by higher U.S. glaucoma revenue from the iDose TR sustained-release implant and growth in international glaucoma procedures.

Corneal health revenue also increased as Photrexa and the early Epioxa launch contributed more U.S. sales. Gross margin was 78%, similar to last year, but higher selling, general and administrative expenses of $92.9 million and research and development spending of $44.1 million kept the company in the red, with a net loss of $19.8 million, or $0.34 per share.

Glaukos ended the quarter with $280.5 million in cash, cash equivalents, short-term investments and restricted cash. The company highlighted an option agreement for potential new drug technology and noted a permanent HCPCS J-code for Epioxa effective July 2026, which is expected to simplify U.S. reimbursement for its new keratoconus therapy.

Rhea-AI Summary

Glaukos Corporation reported Q3 2025 results. Net sales were $133.5 million for the three months ended September 30, 2025, up from $96.7 million a year ago, while net loss narrowed to $16.2 million with basic and diluted net loss per share of $0.28.

Glaucoma products contributed $110.2 million and Corneal Health $23.3 million in the quarter. Gross profit was $104.7 million; operating expenses were $121.1 million, leading to a loss from operations of $16.4 million. Cash and cash equivalents were $98.2 million and short‑term investments $175.5 million at quarter‑end. Total assets were $999.4 million and stockholders’ equity was $769.5 million.

Year to date, net sales reached $364.3 million versus $278.0 million last year, with net loss of $54.0 million. The company closed the Mobius Therapeutics acquisition with $24.5 million consideration and purchased an adjacent Aliso Viejo building for $16.6 million. Accounts receivable rose, driven by iDose TR’s extended payment terms. Shares outstanding were 57,434,740 as of October 29, 2025.